PPH stock forecast, quote, news & analysis

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), McKesson Corp (NYSE:MCK), Teva Pharmaceutical Industries Limited (NYSE:TEVA).

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

The average market capitalization across the VanEck Pharmaceutical ETF ETF is 139.17B. The market cap for tickers in the group ranges from 2.48B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is PDCO at 2.48B.

The average weekly price growth across all stocks in the VanEck Pharmaceutical ETF ETF was -5%. For the same ETF, the average monthly price growth was -9%, and the average quarterly price growth was -3%. BMY experienced the highest price growth at 4%, while ABBV experienced the biggest fall at -17%.

The average weekly volume growth across all stocks in the VanEck Pharmaceutical ETF ETF was 69%. For the same stocks of the ETF, the average monthly volume growth was 173% and the average quarterly volume growth was 125%